MARKET

ADMP

ADMP

Adamis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7483
-0.0217
-2.82%
Opening 12:24 09/23 EDT
OPEN
0.7889
PREV CLOSE
0.7700
HIGH
0.7930
LOW
0.7402
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.2700
MARKET CAP
67.38M
P/E (TTM)
-1.4297
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Dow Tumbles 300 Points; COMPASS Pathways Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 1.11% to 27591.20 while the NASDAQ fell 1.68% to 10,727.08. The S&P also fell, dropping 1.42% to 3,309.30.
Benzinga · 4d ago
Mid-Day Market Update: Nasdaq Turns Lower; Westport Fuel Systems Shares Surge
Midway through trading Friday, the Dow traded down 0.11% to 27872.20 while the NASDAQ fell 0.58% to 10,847.47. The S&P also fell, dropping 0.39% to 3,343.85.
Benzinga · 5d ago
Adamis Pharmaceuticals prices equity offering, shares down 13%
Adamis Pharmaceuticals (ADMP) -13% has priced public offering of 16.1M common shares at $0.62, resulting in gross proceeds of ~$10M. Closing date is September 22.Underwriters can purchase 2.42M additional shares.Net proceeds will be
Seekingalpha · 5d ago
Adamis Pharmaceuticals Announces Pricing Of Offering Of Common Stock At $0.62/Share
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused
Benzinga · 5d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 5d ago
Adamis Pharmaceuticals under pressure after public offering
Adamis Pharmaceuticals (ADMP) falls 10% intends to offer common stock in an underwritten public offering.Underwriters' 30-day option to purchase up to an additional 15% of shares offered in the public offering.Net proceeds to
Seekingalpha · 5d ago
Adamis Pharmaceuticals to launch a public offering of stock
Adamis Pharmaceuticals (ADMP) intends to offer common stock in an underwritten public offering.Underwriters' 30-day option to purchase up to an additional 15% of shares offered in the public offering.Raymond James & Associates, Inc.
Seekingalpha · 5d ago
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today
GlobeNewswire · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMP. Analyze the recent business situations of Adamis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMP stock price target is 1.250 with a high estimate of 1.500 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 78
Institutional Holdings: 7.91M
% Owned: 10.56%
Shares Outstanding: 90.05M
TypeInstitutionsShares
Increased
8
240.13K
New
15
-6.54M
Decreased
6
166.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.34%
Pharmaceuticals & Medical Research
-0.05%
Key Executives
Chairman/Independent Director
Richard Williams
Chief Executive Officer/President/Director
Dennis Carlo
Chief Financial Officer/Senior Vice President - Finance
Robert Hopkins
Senior Vice President/Director
David Marguglio
Vice President - Operations
Karen Daniels
Other
Ronald Moss
Independent Director
Howard Birndorf
Independent Director
Roshawn Blunt
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADMP
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Adamis Pharmaceuticals Corp stock information, including NASDAQ:ADMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMP stock methods without spending real money on the virtual paper trading platform.